Patrick Daly

GU Oncology Now

In an oral presentation at the ESMO Congress 2022, the lead author of the phase 2 CYPIDES trial, Karim Fizazi, discussed preliminary findings on ODM-208&mdash;a first-in-class CYP11A1 inhibitor&mdash;in the treatment of metastatic castration-resistant prostate cancer (mCRPC).According to Fizazi, ODM-208 demonstrated &ldquo;promising antitumor activity&rdquo; in heavily pretreated patients with mCRPC with androgen receptor (AR) ligand binding domain (LBD) mutations. Additionally, ODM-208 was highly effective for blocking the production of steroid hormones that may activate the AR signaling pathway.A total of 43 patients (median years of age, 68) with a prespecified AR LBD mutation were evaluable at the March 17, 2022, data cutoff. Participants received ODM-208 5 mg twice a day alongside dexamethasone and fludrocortisone. Efficacy was evaluated according to prostate-specific antigen (PSA) measures and RECIST response criteria.Among the cohort, 51% of patients had previously received abiraterone and enzalutamide, and 65% had received docetaxel and cabazitaxel. Based on preliminary findings, Fizazi reported that ODM-208 induced a more than 50% best reduction in PSA in over half the participants, as well as at least 4 RECIST partial responses among 17 patients with matured data.Additionally, Fizazi noted that ODM-208 had been well-tolerated and demonstrated a much lower rate of hospitalization for adrenal insufficiency to date when compared with the phase 1 study (2.3% vs 33%, respectively).Overall, Fizazi and colleagues supported the potential value of ODM-208 for treating patients with mCRPC who are resistant to hormone-based therapies. The study is ongoing in 18 centers across France, Finland, the UK, and the US, and more mature data will be presented.View More <a href="https://www.docwirenews.com/esmo-2022/">Prostate Cancer Studies From the ESMO Congress 2022</a>

Assessing ODM-208 in Patients With mCRPC: The CYPIDES Trial

European Society for Medical Oncology Congress 2022

ESMO 2022

ODM-208 showed promising antitumor activity in patients with mCRPC and may have the potential to treat individuals resistant to hormone-based therapies.

ODM-208 in mCRPC

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe